Neovascular Age-related Macular Degeneration

Showing 1 - 25 of 145

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Neovascular Age-related Macular Degeneration Trial (RRG001)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • (no location specified)
Nov 15, 2023

Single Injection of Faricimab for nAMD With Persisting Fluid

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • Glostrup, Denmark
    Miklos Schneider
Nov 3, 2023

Patterns With Brolucizumab in Germany -Retrospective Cohort

Completed
  • Neovascular Age-related Macular Degeneration
    • Porto Salvo, Portugal
      Novartis
    Aug 28, 2023

    Neovascular Age-related Macular Degeneration Trial in Katy, Norfolk (SKG0106)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • SKG0106
    • Katy, Texas
    • +1 more
    Aug 15, 2023

    Neovascular Age-related Macular Degeneration Trial in Suzhou (Aflibercept Ophthalmic, IBI302)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • Aflibercept Ophthalmic
    • IBI302
    • Suzhou, Jiangsu, China
      Innovent Biologics (Suzhou) Co,Ltd.
    Jul 25, 2023

    Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Beijing (Intravitreal injection of IBI302(dose 1),

    Suspended
    • Neovascular Age-related Macular Degeneration
    • Diabetic Macular Edema
    • Intravitreal injection of IBI302(dose 1)
    • +3 more
    • Beijing, Beijing, China
      Peking University People's Hospital
    Jul 17, 2023

    Neovascular Age-related Macular Degeneration Trial (PMC-403)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • (no location specified)
    Jul 11, 2023

    Neovascular Age-related Macular Degeneration Trial in Graz (Aflibercept 40 MG/ML, Faricimab 120 MG/ML)

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • Aflibercept 40 MG/ML
    • Faricimab 120 MG/ML
    • Graz, Styria, Austria
      Department of Ophthalmolgy, Medical University Graz
    Jul 3, 2023

    Neovascular Age-related Macular Degeneration Trial (Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule,

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
    • Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule
    • (no location specified)
    Jun 6, 2023

    Neovascular Age-related Macular Degeneration Trial in Phoenix (CLS-AX, Aflibercept)

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • Phoenix, Arizona
      Retinal Research Institute, LLC
    Jun 4, 2023

    Neovascular Age-related Macular Degeneration Trial (AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • AXT107 Low Dose
    • +2 more
    • (no location specified)
    May 5, 2023

    Neovascular Age-related Macular Degeneration Trial in Shanghai (LX102-C01 Injection)

    Active, not recruiting
    • Neovascular Age-related Macular Degeneration
    • LX102-C01 Injection
    • Shanghai, China
      Shanghai General Hospital, Shanghai Jiao Tong University School
    Apr 14, 2023

    Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Austin (AIV007)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • Diabetic Macular Edema
    • Austin, Texas
      Retina Consultants of Austin
    Jan 16, 2023

    Neovascular Age-related Macular Degeneration Trial in Worldwide (SOK583A1 (40 mg/mL), Eylea EU (40 mg/mL))

    Active, not recruiting
    • Neovascular Age-related Macular Degeneration
    • SOK583A1 (40 mg/mL)
    • Eylea EU (40 mg/mL)
    • Phoenix, Arizona
    • +101 more
    Jan 23, 2023

    Neovascular Age-related Macular Degeneration Trial in Worldwide (brolucizumab)

    Active, not recruiting
    • Neovascular Age-related Macular Degeneration
    • Huntington Beach, California
    • +59 more
    Jan 20, 2023

    Neovascular Age-Related Macular Degeneration Trial in China (Brolucizumab 6mg, Aflibercept 2 mg)

    Recruiting
    • Neovascular Age-Related Macular Degeneration
    • Brolucizumab 6mg
    • Aflibercept 2 mg
    • Guangzhou, Guangdong, China
    • +30 more
    Jan 20, 2023

    Russian Registry of Patients With nAMD

    Terminated
    • Neovascular Age-Related Macular Degeneration
    • nAMD
    • (no location specified)
    Jan 16, 2023

    Neovascular Age-related Macular Degeneration Trial in United States (SUSVIMO (ranibizumab injection), LUCENTIS (ranibizumab

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • SUSVIMO (ranibizumab injection)
    • LUCENTIS (ranibizumab injection)
    • Mesa, Arizona
    • +32 more
    Jan 13, 2023

    Neovascular Age-related Macular Degeneration Trial in United States (OLX10212 is a cell penetrating asymmetric small

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
    • Santa Maria, California
    • +4 more
    Jan 10, 2023

    Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in San Antonio (D-4517.2)

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • Diabetic Macular Edema
    • Los Angeles, California
    • +11 more
    Jan 11, 2023

    Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Mesa, Phoenix (Faricimab PFS Configuration)

    Completed
    • Neovascular Age-related Macular Degeneration
    • Diabetic Macular Edema
    • Faricimab PFS Configuration
    • Mesa, Arizona
    • +2 more
    Jan 2, 2023

    Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

    Active, not recruiting
    • Neovascular Age-related Macular Degeneration
    • Phoenix, Arizona
    • +6 more
    Dec 14, 2022

    Neovascular Age-related Macular Degeneration Trial in Beijing (IBI333)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • IBI333
    • Beijing, Beijing, China
      Peking Union Medical College Hospital, Chinese Academy of Medica
    Nov 28, 2022

    Neovascular Age-related Macular Degeneration Trial in United States (CLS-AX, Anti-VEGF)

    Completed
    • Neovascular Age-related Macular Degeneration
    • Phoenix, Arizona
    • +10 more
    Dec 1, 2022